IRIS
RUGGIERI, Maddalena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.079
AS - Asia 2.584
EU - Europa 1.895
SA - Sud America 713
AF - Africa 137
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.414
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.978
SG - Singapore 1.123
CN - Cina 588
BR - Brasile 570
IT - Italia 339
HK - Hong Kong 302
SE - Svezia 286
RU - Federazione Russa 257
DE - Germania 230
UA - Ucraina 203
VN - Vietnam 172
FR - Francia 167
FI - Finlandia 159
GB - Regno Unito 109
IN - India 86
BD - Bangladesh 63
CI - Costa d'Avorio 62
CA - Canada 50
AR - Argentina 44
JP - Giappone 37
ID - Indonesia 34
IQ - Iraq 31
MX - Messico 31
TR - Turchia 26
ZA - Sudafrica 23
EC - Ecuador 22
VE - Venezuela 22
ES - Italia 21
BE - Belgio 20
PH - Filippine 20
PK - Pakistan 20
IE - Irlanda 18
PL - Polonia 18
CO - Colombia 17
NL - Olanda 14
AT - Austria 13
PY - Paraguay 12
SA - Arabia Saudita 11
TN - Tunisia 11
UZ - Uzbekistan 11
JO - Giordania 10
KE - Kenya 10
LT - Lituania 9
MA - Marocco 9
CL - Cile 8
EG - Egitto 8
IR - Iran 8
PE - Perù 7
CZ - Repubblica Ceca 6
JM - Giamaica 6
MY - Malesia 6
AE - Emirati Arabi Uniti 5
IL - Israele 5
UY - Uruguay 5
BO - Bolivia 4
CH - Svizzera 4
DO - Repubblica Dominicana 4
OM - Oman 4
PT - Portogallo 4
AL - Albania 3
AO - Angola 3
AU - Australia 3
DK - Danimarca 3
NP - Nepal 3
PS - Palestinian Territory 3
TH - Thailandia 3
AZ - Azerbaigian 2
BG - Bulgaria 2
GT - Guatemala 2
HR - Croazia 2
KR - Corea 2
KZ - Kazakistan 2
PA - Panama 2
RO - Romania 2
RS - Serbia 2
SN - Senegal 2
TT - Trinidad e Tobago 2
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
GM - Gambi 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
QA - Qatar 1
Totale 11.408
Salva come PNG Salva come JPEG
Città #
Ashburn 593
Singapore 590
Chandler 522
Fairfield 500
Woodbridge 473
Jacksonville 454
San Jose 310
Hong Kong 302
Houston 265
Nyköping 220
Ann Arbor 214
Wilmington 198
Seattle 182
Cambridge 171
Beijing 169
Lawrence 106
Los Angeles 106
Roxbury 103
Nanjing 102
Lauterbourg 101
Bari 84
Dallas 80
New York 78
Des Moines 69
Boardman 68
Abidjan 62
Chicago 56
Helsinki 56
Ho Chi Minh City 53
Munich 48
Brooklyn 46
Buffalo 42
Inglewood 42
Princeton 40
São Paulo 40
Council Bluffs 37
Santa Clara 37
Marseille 33
Tokyo 31
Hanoi 30
Salt Lake City 29
San Diego 28
Nanchang 25
Rio de Janeiro 24
Jiaxing 23
Shenyang 23
Moscow 22
Brussels 20
Frankfurt am Main 20
Tianjin 20
Falkenstein 19
Dublin 18
Hebei 18
Belo Horizonte 17
Chennai 17
Jakarta 17
Toronto 17
Milan 15
Warsaw 15
Miami 14
Dearborn 13
London 13
Mexico City 13
Nuremberg 13
Orem 13
Elk Grove Village 12
Johannesburg 12
Mottola 12
North Bergen 12
Phoenix 12
Pune 12
Rome 12
Augusta 11
Baghdad 11
Da Nang 11
Montreal 11
Norwalk 11
San Francisco 11
Stockholm 11
Tampa 11
Tashkent 11
Denver 10
Dong Ket 10
El Paso 10
Guangzhou 10
Assisi 9
Changsha 9
Haiphong 9
Imbersago 9
Nairobi 9
Paris 9
Amman 8
Bacolod City 8
Campinas 8
Caracas 8
Dhaka 8
Manchester 8
Poplar 8
Salvador 8
Turku 8
Totale 7.528
Salva come PNG Salva come JPEG
Nome #
Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Diagnostic Biomarkers in Autism Spectrum Disorders: A Preliminary Study 270
Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis 231
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 179
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. 178
Age-related changes of serum N-acetyl-aspartate in healthy controls. 174
Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis 165
Clinical, histologic and prognostic features of clinically amyopathic dermatomyositis 160
Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies 160
Development of an aquaporin-4 orthogonal array of particle-based ELISA for neuromyelitis optica autoantibodies detection 155
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of Multiple Sclerosis 154
ANTINFLAMMATORY EFFECTS OF RIFNB-1B IN MULTIPLE SCLEROSIS: LONGITUDINAL CHANGES OF THE SERUM SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 (SICAM-1), TNFA AND T-CELL SUBSETS 148
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment 148
IFNβ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism 146
Glatiramer Acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from Multiple Sclerosis patients 145
Anti-SAE dermatomyositis: clinical and histologic characteristics from a monocentric Italian cohort 144
IMMUNOPATOLOGIA DELLA SCLEROSI MULTIPLA 144
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 143
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 142
Cerebrospinal Fluid and Clinical Profiles in Adult Type 2–3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience 140
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. 139
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 136
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 132
Serum levels of N-acetylaspartate in Huntington's disease: Preliminary results. 123
B and T Immunoregulation: A New Insight of B Regulatory Lymphocytes in Autism Spectrum Disorder 122
A population-based surveillance Italian study of Interferon beta treatment in Multiple Sclerosis patients: relationships between neutralizing antibodies production and clinical outcomes 118
Cerebrospinal fluid analysis and the determination of oligoclonal bands 118
Analisi fenotipica di linfociti T di pazienti con Sclerosi Multipla (SM) nel sangue periferico ed in coltura con e senza aggiunta di mitogeni 117
ADHESION MOLECULES AND MATRIX METALLOPROTEINASES IN MS: EFFECTS INDUCED BY INTERFERON BETA 117
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes 115
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. 114
Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD) 113
CHANGES OF NAIVE AND EFFECTOR/MEMORY T-CELL SUBSETS AND SERUM SOLUBLE ICAM-1 INDUCED BY RIFNB-1B IN MS 111
Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding 111
Serum levels of N-acetyl-aspartate in migraine and tension-type headache. 111
Beta Amyloid 1-40 peptide selectively downregulates MMP-9 production in differentiated SH-SY5Y neuronal cell line 109
Serum levels of N-acetyl-aspartate in migraine and tension-type headache. 109
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica 109
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 109
Is cerebrospinal fluid amyloid-β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients? 108
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 108
Autophagy increase in Merosin-Deficient Congenital Muscular Dystrophy type 1A 107
Antinflammatory effects of rIFNb-1b in multiple sclerosis: longitudinal changes of the serum soluble Intercellular Adhesion Molecule-1 (sICAM-1), TNFa and T-cell subsets 105
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. 105
Neurofilament ELISA validation 105
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 104
Correlations between neutralizing antibodies production and clinical outcomes: analysis in a population-based surveillance italian study of interferon beta treatment in multiple sclerosis patients 104
A LONGITUDINAL ANALYSIS OF SERUM SOLUBLE ICAM-1 (SICAM-1), TNFA AND T-CELL SUBSETS IN MULTIPLE SCLEROSIS (MS) PATIENTS DURING RIFNB-1B TREATMENT 102
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 100
Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients 99
Italian studies on early-onset multiple sclerosis: the present and the future 99
Glatiramer acetate in multiple sclerosis: a review 97
MMP-9 and 2 activities and TIMPs in MS: differences between early and chronic disease 96
Cerebrospinal Fluid and Serum Neurofilament Light Chain Levels in ALS Patients 96
Serum Soluble ICAM-1 and Gelatinase B Novel Markers of Clinical Efficacy of the RIFN-beta-1b in Relapsing-Remitting Multiple Sclerosis 96
CHANGES OF SERUM ICAM-1 AND MMP-9 INDUCED BY RIFNB-1B TREATMENT IN RELAPSING-REMITTING MS 95
ANALISI DEL POLIMORFISMO GENICO E DELLA PRODUZIONE LIMFOMONOCITARIA DI TNF-ALPHA IN PAZIENTI CON SCLEROSI MULTIPLA (SM) 95
Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients 94
Decreased levels of serum Gelatinase B in MS patients treated with rIFN-beta-1b 94
Plasma pentraxin 3 in idiopathic inflammatory myopathies: a possible new biomarker of disease activity 90
Elevated Expression of ADAM10 in Skeletal Muscle of Patients with Idiopathic Inflammatory Myopathies Could Be Responsible for FNDC5/Irisin Unbalance 90
Neutralizing antibodies during treatment of relapsing Multiple Sclerosis patients with three interferon beta: correlation with clinical outcomes 89
Serum MMPs and TIMPs in Multiple Sclerosis: differences between early and chronic disease 88
UN ANNO DI TRATTAMENTO CON INTERFERONE B-1B INCREMENTA I LIVELLI SIERICI DI SICAM-1 E RIPRISTINA LA FUNZIONE SOPPRESSORIA DEI T-LINFOCITI IN PAZIENTI CON SM RELAPSING-REMITTING 88
Bcl-2, Bax, Cytocrome-c mitochondria mediated apoptosis proteins during Glatiramer Acetate treatment in Multiple Sclerosis patients 88
Interferone beta (IFNb) e barriera emato-encefalica nella Sclerosi Multipla: effetto su molecole di adesione e metalloproteasi 87
Interferon-b treatment in relapsing remitting multiple sclerosis: results of an observational study in southern Italy 84
Novel anti-inflammatory properties of rIFN-beta-1b in RR MS: recovery of T-suppression and increase of serum sICAM-1 84
Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke 84
RIFNB DOWNREGULATES TNFA-INDUCED ICAM-1 EXPRESSION ON BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BEMC) AND INCREASES SERUM SOLUBLE ICAM-1 (SICAM-1) IN RR MS 83
Standard (SD) and triple dose (TD) gadolinium (Gd) enhancing lesions are associated with a similar degree of MMP-9 and TIMP-1 involvement at the blood-brain barrier (BBB) level in Multiple Sclerosis (MS) 83
CHANGES OF SERUM SOLUBLE ICAM-1 AND MATRIX METALLOPROTEINASE-9 DURING INTERFERON BETA-1B TREATMENT IN RR MS 82
N-Acetyl-Aspartate (NAA) and Neurofilament Light-Chain (NF-L) in Biological Fluids as Markers of Neurodegeneration in ALS 81
CHANGES OF SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 (SICAM-1) LEVELS INDUCED BY CORTICOSTEROIDS AND RIFN-BETA-1B IN MULTIPLE SCLEROSIS AND GUILLAIN-BARRÉ SYNDROME 80
Modificazioni dei livelli sierici di ICAM-1 solubile (sICAM.1), e Gelatinasi A e B e sottopopolazioni T-linfocitarie di sangue periferico indotte dal trattamento con interferone-beta-1b (IFN-BETA-1B) in pazienti con Sclerosi Multipla (SM) Relapsing-Remitting (RR): Relazione con la produzione di anticorpi neutralizzanti anti-interferone (NABs) 79
Interferon-b treatment in relapsing remitting multiple sclerosis: results of an observational study in southern Italy 78
Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis 77
STUDIO IN VITRO DI POPOLAZIONI LINFOMONOCITARIE CD45R+ E CD29+ 76
LFA-1 expressing CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFNb-1a 76
Changes of serum soluble ICAM-1 and matrix metalloproteinas-9 (MMP-9) induced by Interferon beta-1b treatment in relapsing-remitting multiple sclerosis 76
Decreased levels of serum gelatinase B in MS patients during the treatment with rIFN-beta-1b 75
LFA-1 EXPRESSION ON CD4+CD45RO+ PBTLS DURING RIFN-BETA-1A TREATMENT IN RR MS: IN VIVO AND IN VITRO STUDY 74
LFA-1 EXPRESSION ON CD4+CD45RO+ PERIPHERAL BLOOD T-LYMPHOCYTES: IN VIVO AND IN VITRO CHANGES INDUCED BY RECOMBINANT INTERFERON-BETA-1A (RIFN-BETA-1A) IN RELAPSING-REMITTING (RR) MULTIPLE SCLEROSIS (MS) 73
Changes of serum sICAM-1 and MMP-9 induced by rIFN beta-1b treatment in relapsing-remitting MS 73
Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies 73
null 72
Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes 72
NMO-IgG and AQP-4 antibodies in different demyelinating disease phenotypes: correlations with clinical and paraclinical parameters 71
RIFN BETA-1A AND SICAM-1 EFFECTS ON CD4+CD45RO+ PBTLS EXPRESSING LFA-1 IN RR MS: IN VIVO AND IN VITRO STUDY 71
null 71
Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics 70
SOPLUBLE INTERCELLULAR ADHESION MOLECULE-1 (SICAM-1) NEL SIERO E LIQUOR DI PAZIENTI CON SCLEROSI MULTIPLA REMITTENTE CLINICAMENTE ATTIVA: CORRELAZIONI CON LESIONI RMI CHE ASSUMONO GADOLINIO E CON PARAMETRI LIQUORALI 68
CSF and serum soluble adhesion molecules in Multiple Sclerosis 68
VALUTAZIONE POST-MARKETING DI SICUREZZA DELL' INTERFERONE-BETA (IFN-BETA) IN PAZIENTI CON SCLEROSI MULTIPLA (SM) RELAPSING-REMITTING (RR) NELL' ITALIA MERIDIONALE. RICERCA SCIENTIFICA DELLE 67
MMPS AND TIMPS ARE DIFFERENTLY RELATED TO MS COURSES AND PHASES OF THE DISEASE 66
Serum N-acetyl-aspartate in Relapsing Remitting Multiple Sclerosis 65
IFNB-1B TREATMENT EFFECTS ON SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 SERUM LEVELS AND T-CELL SUBSETS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS. 12TH CONGRESS OF THE EUROPEAN COMMITTE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) 64
MMPs and TIMPs involvement at the blood-brain barrier level in MS: comparison between patients enhancing with different doses of gadolinium during rIFNb-1a treatment 64
Soluble Intercellular Adhesion Molecule-1 in serum and cerebrospinal fluid of demyelinating disease of the central and peripheral nervous system 63
Matrix metalloproteinases and disease corse in Multiple Sclerosis 63
null 62
Totale 10.556
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.911
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.911
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021246 0 0 0 0 0 0 0 0 0 122 83 41
2021/2022673 23 111 19 19 25 35 28 42 40 21 135 175
2022/20231.298 172 121 83 133 157 176 11 145 234 1 30 35
2023/2024391 47 70 24 24 24 90 28 21 4 10 3 46
2024/20252.092 62 36 146 55 46 152 155 187 67 129 443 614
2025/20263.632 621 206 286 453 458 241 459 135 421 352 0 0
Totale 11.579